0001104659-20-137967.txt : 20201221
0001104659-20-137967.hdr.sgml : 20201221
20201221133257
ACCESSION NUMBER: 0001104659-20-137967
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201217
FILED AS OF DATE: 20201221
DATE AS OF CHANGE: 20201221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRAYZEL DAVID S.
CENTRAL INDEX KEY: 0001732786
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38459
FILM NUMBER: 201403435
MAIL ADDRESS:
STREET 1: C/O SURFACE ONCOLOGY
STREET 2: 50 HAMPSHIRE ST., 8TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Surface Oncology, Inc.
CENTRAL INDEX KEY: 0001718108
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 HAMPSHIRE STREET, 8TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-714-4096
MAIL ADDRESS:
STREET 1: 50 HAMPSHIRE STREET, 8TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
a4.xml
4
X0306
4
2020-12-17
0
0001718108
Surface Oncology, Inc.
SURF
0001732786
GRAYZEL DAVID S.
C/O SURFACE ONCOLOGY, INC.
50 HAMPSHIRE STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2020-12-17
4
S
0
1700000
18.10
D
2945453
I
See Footnote #
Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. The Reporting Persons owns an interest in AVA IX LP and disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Mr. Grayzel is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The high, low and average for the shares sold were all $8.10. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.
These shares are held directly by Atlas IX. The sole general partner of Atlas IX is AVA IX LP. AVA IX LLC is the sole general partner of AVA IX LP. The Reporting Persons owns an interest in AVA IX LP and disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Mr. Grayzel is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
By: /s/ Frank Castellucci -Attorney in Fact
2020-12-21